Fact CheckerSign in

NCT01241305Recruiting

One-Time DNA Study for Vasculitis

VCRC Genetic Repository One-Time DNA Protocol

Source: ClinicalTrials.gov · Last updated 22 Jan 2026

Brief summary (registry, in English)

The purpose of this study is to identify genes that increase the risk of developing vasculitis, a group of severe diseases that feature inflammation of blood vessels. Results of these studies will provide vasculitis researchers with insight into the causes of these diseases and generate new ideas for diagnostic tests and therapies, and will be of great interest to the larger communities of researchers investigating vasculitis and other autoimmune, inflammatory, and vascular diseases.

Status (registry)
Recruiting
Study type
Observational
Enrollment
1000 (estimated)
First submitted
22 Oct 2010
Start date
Oct 2010
Primary completion date
Aug 2028
Lead sponsor
University of Pennsylvania
NCT number
NCT01241305

What you commit to

  • Study type: Observational
  • Planned participants: 1000
  • From Oct 2010 to the primary completion date, Aug 2028
  • 14 sites in 3 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

  • 1\. Diagnostic criteria for Giant Cell Arteritis Age at disease onset \>50 years (required)
  • New onset or new type of localized pain in the head
  • Temporal artery abnormality (i.e. temporal artery tenderness to palpation or decreased pulsation, unrelated to arteriosclerosis of cervical arteries)
  • ESR of \>40mm in the first hour by the Westergren method
  • Abnormal artery biopsy (i.e. temporal artery biopsy showing vasculitis characterized by a predominance of mononuclear cell infiltration or granulomatous inflammation, usually with multinucleated giant cells)
  • Large Vessel Vasculitis (LVV) by angiogram or biopsy not explained by something else
  • 2\. Diagnostic criteria for Takayasu's Arteritis
  • Age at disease onset \<50 years
  • Claudication of extremities
  • Decreased brachial artery pulse (one or both arteries)
  • Blood pressure difference of \>10mm Hg between the arms
  • Bruit over subclavian arteries or aorta
  • Arteriogram abnormalities compatible with TAK (includes conventional dye angiography or MR angiography or CT angiography)
  • 3\. Diagnostic criteria for Polyarteritis Nodosa Major criteria (not explained by other causes) felt by investigator to be due to vasculitis
  • Arteriographic abnormality
  • Presence of granulocyte or mixed leukocyte infiltrate in an arterial wall on biopsy
  • Mononeuropathy or polyneuropathy
    • Minor criteria (not explained by other causes) felt by investigator to be due to vasculitis
  • Weight loss \> 4 kg
  • Livedo reticularis, cutaneous ulcerations, or skin nodules
  • Testicular pain or tenderness
  • Myalgias
  • Diastolic blood pressure \> 90 mm Hg
  • Elevated BUN or serum creatinine levels
  • Ischemic abdominal pain
    • Isolated cutaneous Polyarteritis Nodosa 1. Biopsy-proven cutaneous PAN
  • 4\. Diagnostic criteria for Granulomatosis with Polyangiitis (Wegener's) (GPA) and Microscopic Polyangitis (MPA)
  • Diagnosis of GPA or MPA. Widely accepted diagnostic criteria, as opposed to classification criteria or definitions, have not been developed for GPA \& MPA.
  • For diagnosis of GPA meets at least 2 of the following 5 modified ACR criteria:
    • Nasal or oral inflammation with oral ulcers or nasal discharge with pus or blood
    • Abnormal chest radiograph with nodules, fixed infiltrates, or cavities
    • Urinary sediment with microhematuria or red cell casts
    • Granulomatous inflammation within the wall of an artery or in the perivascular area on biopsy
    • Antineutrophil cytoplasmic antibody (ANCA) positive by enzyme immunoassay for either PR3- or MPO-ANCA
  • For diagnosis of MPA, meets the Chapel Hill Consensus Conference Definition for MPA:
    • Necrotizing vasculitis, with few or no immune deposits, that affects small vessels (i.e., capillaries, venules, arterioles)
    • Necrotizing arteritis involving small- and medium-sized arteries may be present
    • Necrotizing glomerulonephritis is very common
    • Pulmonary capillaritis often occurs
  • 5\. Diagnostic criteria for Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)
  • Asthma
  • Peak peripheral blood eosinophilia of \>10% of total WBC
  • Peripheral neuropathy attributable to vasculitis
  • Transient pulmonary infiltrates on chest imaging studies
  • Paranasal sinus abnormalities or nasal polyposis
  • Eosinophilic inflammation on tissue biopsy
    • If patients have 4 of the above 6 criteria but lack clearcut documentation of small vessel vasculitis, they are also eligible for enrollment.
    • General Exclusion Criteria:
  • Inability to give informed consent and to sign the consent form
  • Enrolled in VCRC protocols 5502, 5503, 5504, 5505, 5506, 5522, or 5523
  • Unwilling to provide blood for DNA collection

Age in the registry: 7 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (14)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
St. Joseph's Healthcare
Coordinator of this site? Confirm its status
HamiltonCanadaRecruiting
Mount Sinai Hospital
Coordinator of this site? Confirm its status
TorontoCanadaRecruiting
University of Michigan
Coordinator of this site? Confirm its status
Ann ArborUnited StatesCompleted
Northwestern University
Coordinator of this site? Confirm its status
ChicagoUnited StatesRecruiting
Cleveland Clinic
Coordinator of this site? Confirm its status
ClevelandUnited StatesCompleted
University of Kansas Medical Center
Coordinator of this site? Confirm its status
Kansas CityUnited StatesCompleted
Cedars-Sinai Medical Center
Coordinator of this site? Confirm its status
Los AngelesUnited StatesCompleted
Hospital for Special Surgery
Coordinator of this site? Confirm its status
New YorkUnited StatesCompleted
University of Pennsylvania
Coordinator of this site? Confirm its status
PhiladelphiaUnited StatesRecruiting
University of Pittsburgh
Coordinator of this site? Confirm its status
PittsburghUnited StatesCompleted
Mayo Clinic
Coordinator of this site? Confirm its status
RochesterUnited StatesCompleted
University of Utah
Coordinator of this site? Confirm its status
Salt Lake CityUnited StatesCompleted
University of California San Francisco
Coordinator of this site? Confirm its status
San FranciscoUnited StatesCompleted
Istanbul University
Coordinator of this site? Confirm its status
IstanbulTurkey (Türkiye)Completed

This page is information, not medical advice. Discuss any trial with your doctor.